# From Preparticipation Screening to Diagnosis: Long-Term Outcomes of Athletes with Ventricular Repolarization Abnormalities and Normal Echocardiography

**Authors:** Massimiliano Bianco, Fabrizio Sollazzo, Stefania Manes, Andrea Giovanni Cristaudo, Gloria Modica, Riccardo Monti, Michela Cammarano, Paolo Zeppilli, Vincenzo Palmieri

PMC · DOI: 10.3390/jpm16030136 · 2026-03-01

## TL;DR

This study tracks athletes with heart electrical issues over time, finding that persistent abnormalities are linked to later heart diagnoses, suggesting the need for long-term monitoring.

## Contribution

The study identifies that persistent resting ventricular repolarization abnormalities predict future cardiovascular diagnoses in athletes with initially normal echocardiograms.

## Key findings

- Over 50% of athletes with ventricular repolarization abnormalities received a cardiovascular diagnosis during long-term follow-up.
- Persistence of resting VRA was significantly associated with a higher likelihood of diagnosis, unlike exercise-induced changes.
- Advanced imaging played a key role in identifying heart conditions not detected by initial tests.

## Abstract

Background/Objectives: Ventricular repolarization abnormalities (VRA) represent a grey area in athlete screening: some patterns are physiological, while others are precursors to heart disease. Objective: to clarify the natural history of VRA and the associated factors of structural diagnosis. Methods: Retrospective observational single-center study of athletes with resting or stress VRA at the first evaluation, with normal echocardiography; minimum follow-up of 2 years. Clinical data, resting and stress ECG, echocardiography, and selective advanced imaging throughout follow-up were collected. Primary outcome: cardiovascular diagnosis at follow-up; time-to-event analysis and associations between ECG characteristics and diagnosis. Results: Fifty-three athletes (mean age 22.2 ± 9.2 years; 92.5% male) were included; 60.4% had resting VRA, and 100% had exercise-induced VRA at baseline. Over 7.3 ± 4.5 years, 28/53 (52.8%) received a diagnosis; median time-to-detection was 7.0 years (95% CI 6.0–not reached); RMST10 was 6.7 years (95% CI 5.7–7.7). Diagnoses included hypertrophic cardiomyopathy (24.5%), non-ischaemic left-ventricular scar (11.3%), myocardial bridging (7.5%), hypertensive remodelling (5.7%), coronary anomaly (1.9%), and ventricular pre-excitation (1.9%). Persistence of resting VRA from baseline to follow-up was more frequent in athletes with a final diagnosis (p = 0.01), whereas topography and exercise-induced abnormalities did not discriminate groups. Advanced imaging contributed substantially to case ascertainment. No major adverse cardiovascular events have been identified throughout follow-up. Conclusions: In athletes with screening-detected VRA and normal echocardiography, persistence of resting VRA was associated with higher detection of a cardiovascular diagnosis, while exercise-induced changes alone show limited diagnostic yield. The long median time-to-detection supports prolonged, pre-planned surveillance, with priority for advanced imaging in profiles with persistent abnormalities. These findings align with a risk-adapted, personalized management strategy in sports cardiology.

## Linked entities

- **Diseases:** hypertrophic cardiomyopathy (MONDO:0005045)

## Full-text entities

- **Diseases:** thyroid disorders (MESH:D013959), channelopathies (MESH:D053447), scar (MESH:D002921), injury to (MESH:D014947), ventricular pre (MESH:D014927), hypertrophic and dilated cardiomyopathies (MESH:D002311), arrhythmic (OMIM:212500), subarachnoid haemorrhage (MESH:D013345), arrhythmogenic cardiomyopathy (MESH:D019571), angina (MESH:D000787), -compaction (MESH:D056830), mitral valve prolapse (MESH:D008945), anaemia (MESH:D000743), cardiovascular (MESH:D002318), stroke (MESH:D020521), anomalous origin of coronary arteries (MESH:D000080038), EPS (MESH:D001480), myopericarditis (MESH:D010146), electrolyte disorders (MESH:D014883), hypertensive remodelling (MESH:D006973), bundle-branch block (MESH:D002037), myocardial bridge (MESH:D054084), arrhythmias (MESH:D001145), coronary anomaly (MESH:D003330), HCM (MESH:D002312), coronary artery anomaly (MESH:D003324), NLVS (MESH:D018487), ST-segment depression (MESH:D000072657), depression (MESH:D003866), VRA (MESH:D018754), valve defects (MESH:D006349), pulmonary embolism (MESH:D011655), sudden death (MESH:D003645), ischaemic (MESH:D018917), ventricular remodeling (MESH:D020257), arterial hypertension (MESH:D000081029), ischaemia (MESH:D007511), uncompensated (MESH:D015812), heart conditions (MESH:D006331), cardiomyopathies (MESH:D009202)
- **Chemicals:** antiandrogenic steroids (-)
- **Species:** Athletes (genus) [taxon 1337349], Homo sapiens (human, species) [taxon 9606]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13027607/full.md

---
Source: https://tomesphere.com/paper/PMC13027607